32nd Annual Symposium on the Etiology, Pathogenesis, and Treatment of Parkinson Disease and Other Movement Disorders

Presented by the Parkinson Study Group in collaboration with the Huntington Study Group, Dystonia Study Group, Tourette Syndrome Study Group, Cooperative Ataxia Group and Tremor Research Group

Saturday, April 6, 2019
Sheraton Grand at Wild Horse Pass
Phoenix, AZ
8:00 a.m. – 1:30 p.m.

Theme: Advancing Clinical Trials in PD and Neurodegenerative Disorders:

8:00-8:10 Intro/Acknowledgements: Jeff Bronstein, Chair, PSG Symposium Committee

PLATFORM ABSTRACT PRESENTATIONS: (10 min/5 min Q&A)

8:10-8:25 Parkinson Disease Abstract Presentation: to be determined
8:25-8:40 Other Movement Disorder Abstract Presentation: to be determined

KEYNOTE PRESENTATIONS: (45 min/10 min Q&A)

8:40-9:35 PRESENTATION: The rationale for targeting LRRK2 and GBA
Andrew West, PhD, Professor, Duke Center for Neurodegeneration Research, Departments of Pharmacology and Cancer Biology and Neurology (45 min talk/10 min Q&A)

9:35-10:30 PRESENTATION: Parkinson Phenotype of Patients with LRRK2 and GBA mutations
Susan Bressman, MD, Professor and Chair, Mount Sinai Beth Israel (45 min talk/10 min Q&A)

10:30-12:00 FORMAL POSTER SESSION
a) 10:30-11:15: Focus on the latest diagnostic/therapeutic research on PD.
b) 11:15-12:00: Focus on the latest diagnostic/therapeutic research on Huntington disease, Dystonia, Ataxia and Tourette syndrome.

12:00-12:55 PRESENTATION: The Current Status of Clinical Trials Targeting Patients with LRRK2 and GBA mutations
Brian Fiske, PhD, Senior Vice President, Research Programs, The Michael J. Fox Foundation for Parkinson’s Research (45 min talk/10 min Q&A)

12:55-1:25 PRESENTATION: Patient Perspectives on Living with an Inherited Form of Parkinson Disease
Mr. Ofer Nemirovsky (20 min talk/10 min Q&A)

1:25-1:30 Presentation of Abstract Awards and Closing Remarks: Jeff Bronstein